Newsom Lydia C
Mercer University College of Pharmacy, Atlanta, GA, USA
Ann Pharmacother. 2015 Apr;49(4):484-93. doi: 10.1177/1060028014564181. Epub 2014 Dec 19.
A new guideline for the treatment of blood cholesterol was recently released by the American College of Cardiology (ACC) and the American Heart Association (AHA), serving as an update to the National Cholesterol Education Program's (NCEP) Adult Treatment Panel III cholesterol guideline first released in 2001. With significant changes to key definitions, treatment strategy, and therapy selection, the guideline has transformed the treatment of blood cholesterol and also created controversy within the health care community. This controversy is largely focused on appropriate identification and treatment of patients for the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Whereas statins play an integral role in the treatment and secondary prevention of ASCVD, their use for primary prevention is less clearly defined. It is imperative that health care providers are well versed in the concepts and controversies of the new guideline recommendations for primary prevention of ASCVD and can effectively assess the risks and benefits of statin therapy in this patient population.
美国心脏病学会（ACC）和美国心脏协会（AHA）最近发布了一项新的血液胆固醇治疗指南，作为2001年首次发布的国家胆固醇教育计划（NCEP）成人治疗小组III胆固醇指南的更新。该指南在关键定义、治疗策略和治疗选择方面有重大变化，改变了血液胆固醇的治疗方式，也在医疗界引发了争议。这场争议主要集中在动脉粥样硬化性心血管疾病（ASCVD）一级预防中患者的适当识别和治疗。虽然他汀类药物在ASCVD的治疗和二级预防中发挥着不可或缺的作用，但其在一级预防中的使用定义不太明确。医疗服务提供者必须精通ASCVD一级预防新指南建议的概念和争议，并能有效评估该患者群体中他汀类药物治疗的风险和益处。
